Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Decarboxylase typically refers to the enzyme aromatic L-amino acid decarboxylase (AADC or DOPA decarboxylase). In the context of dopamine physiology and therapeutics, this enzyme is crucial for converting L-DOPA (levodopa) into dopamine in the body. The use of DOPA decarboxylase relates directly to the treatment of Parkinson’s disease, a neurological disorder characterized by dopamine deficiency. When patients are treated with L-DOPA, it must be converted into dopamine to exert its therapeutic effect. However, because peripheral conversion of L-DOPA to dopamine can cause side effects and reduce central nervous system availability, drugs called DOPA decarboxylase inhibitors (such as carbidopa or benserazide) are co-administered to inhibit this enzyme outside the brain, allowing more L-DOPA to reach the brain where it can be converted to dopamine.

The involvement of decarboxylase in dopamine synthesis is well-established and forms the basis for standard Parkinson’s disease therapy. Numerous clinical studies and decades of therapeutic experience validate this mechanism. Therefore, the use of decarboxylase (more accurately, its inhibition) is supported by robust scientific evidence in the context of supporting the dopamine system and managing related disorders.

More about Decarboxylase
More about Dopamine

Other ingredients that support Dopamine

Other body systems supported by Decarboxylase

Products containing Decarboxylase